- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Adverum Biotechnologies Inc (ADVM)
Adverum Biotechnologies Inc stock price live, this page displays NASDAQ ADVM stock exchange data. View the ADVM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Adverum Biotechnologies Inc real time stock price chart below.
What Is the Adverum Biotechnologies Inc Stock Price Today?
The Adverum Biotechnologies Inc stock price today is 2.700.
What Is the Stock Symbol for Adverum Biotechnologies Inc?
The stock symbol for Adverum Biotechnologies Inc is ""ADVM.""
What Stock Exchange Does Adverum Biotechnologies Inc Trade On?
Adverum Biotechnologies Inc is listed and trades on the NASDAQ stock exchange.
Is Adverum Biotechnologies Inc a Good Stock to Buy?
Determining whether Adverum Biotechnologies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADVM quote. (ISIN: US00773U2078)
What Is the Adverum Biotechnologies Inc Stock Price Today?
The Adverum Biotechnologies Inc stock price today is 2.700.
What Is the Stock Symbol for Adverum Biotechnologies Inc?
The stock symbol for Adverum Biotechnologies Inc is ""ADVM.""
What Stock Exchange Does Adverum Biotechnologies Inc Trade On?
Adverum Biotechnologies Inc is listed and trades on the NASDAQ stock exchange.
Is Adverum Biotechnologies Inc a Good Stock to Buy?
Determining whether Adverum Biotechnologies Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ADVM quote. (ISIN: US00773U2078)
2.700
+0.030(+1.12%)
Closed·
After Hours
2.580-0.120(-4.44%)
·
Fair Value
An estimate of a Adverum Biotechn's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.605
2.750
52 wk Range
1.780
8.560
ADVM Scorecard
Full Analysis
Quickly burning through cash
ADVM is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Adverum Biotechn's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.6052.750
52 wk Range
1.7808.560
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ADVM Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Adverum Biotechn's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
19.750
Upside
+631.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings downwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
Adverum Biotechnologies Inc Company Profile
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Adverum Biotechnologies Inc SWOT Analysis
Gene Therapy Pionee | Adverum Biotechnologies leads in ocular gene therapies, with pivotal trials for wet AMD treatment progressing ahead of schedule, showcasing operational efficiency |
Safety Innovations | Explore Adverum's efforts to enhance treatment safety through lower doses and increased steroid exposure, potentially improving the therapeutic index |
Financial Tightrope | Delve into Adverum's financial challenges as it balances a $126 million cash position against the high costs of clinical trials, with analyst price targets ranging from $5 to $40 |
Market Dynamics | Learn how Adverum navigates a competitive landscape, facing challenges from emerging long-acting TKIs while targeting the substantial wet AMD treatment market |
Compare ADVM to Peers and Sector
Metrics to compare | ADVM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipADVMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −2.0x | −0.5x | |
PEG Ratio | −0.01 | −0.02 | 0.00 | |
Price/Book | 2.1x | 3.9x | 2.6x | |
Price / LTM Sales | 56.4x | 82.2x | 3.2x | |
Upside (Analyst Target) | - | 186.4% | 41.7% | |
Fair Value Upside | Unlock | 20.8% | 6.1% | Unlock |
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 19.750
(+631.48% Upside)
Earnings
Latest Release
May 14, 2025
EPS / Forecast
-2.25 / -1.55
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Adverum Biotechn Trade On?
Adverum Biotechn is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Adverum Biotechn?
The stock symbol for Adverum Biotechn is "ADVM."
What Is the Adverum Biotechn Market Cap?
As of today, Adverum Biotechn market cap is 56.40M.
What Is Adverum Biotechn's Earnings Per Share (TTM)?
The Adverum Biotechn EPS (TTM) is -7.22.
From a Technical Analysis Perspective, Is ADVM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Adverum Biotechn Stock Split?
Adverum Biotechn has split 1 times.
How Many Employees Does Adverum Biotechn Have?
Adverum Biotechn has 155 employees.
What is the current trading status of Adverum Biotechn (ADVM)?
As of 26 Jul 2025, Adverum Biotechn (ADVM) is trading at a price of 2.70, with a previous close of 2.67. The stock has fluctuated within a day range of 2.61 to 2.75, while its 52-week range spans from 1.78 to 8.56.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.